Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

ContextBreast cancer estrogen-receptor (ER) status is useful in predicting benefit from endocrine therapy. It may also help predict which patients benefit from advances in adjuvant chemotherapy.ObjectiveTo compare differences in benefits from adjuvant chemotherapy achieved by patients with ER-negative vs ER-positive tumors.Design, Setting, and PatientsTrial data from the Cancer and Leukemia Group B and US Breast Cancer Intergroup analyzed; patient outcomes by ER status compared using hazards over time and multivariate models. Randomized trials comparing (1): 3 regimens of cyclophosphamide, doxorubicin, and fluorouracil (January 1985 to April 1991); (2) 3 doses of doxorubicin concurrent with cyclophosphamide, with or without subsequent paclitaxel (May 1994 to April 1997); (3) sequential doxorubicin, paclitaxel, and cyclophosphamide with concurrent doxorubicin and cyclophosphamide followed by paclitaxel, and also 3-week vs 2-week cycles (September 1997 to March 1999). A total of 6644 node-positive breast cancer patients received adjuvant treatment.Main Outcome MeasuresDisease-free and overall survival.ResultsFor ER-negative tumors, chemotherapy improvements reduced the relative risk of recurrence by 21%, 25%, and 23% in the 3 studies, respectively, and 55% comparing the lowest dose in the first study with biweekly cycles in the third study. Corresponding relative risk reductions for ER-positive tumors treated with tamoxifen were 9%, 12%, and 8% in the 3 studies, and 26% overall. The overall mortality rate reductions associated with chemotherapy improvements were 55% and 23% among ER-negative and ER-positive patients, respectively. All individual ER-negative comparisons and no ER-positive comparisons were statistically significant. Absolute benefits due to chemotherapy were greater for patients with ER-negative compared with ER-positive tumors: 22.8% more ER-negative patients survived to 5 years disease-free if receiving chemotherapy vs 7.0% for ER-positive patients; corresponding improvements for overall survival were 16.7% vs 4.0%.ConclusionAmong patients with node-positive tumors, ER-negative breast cancer, biweekly doxorubicin/cyclophosphamide plus paclitaxel lowers the rate of recurrence and death by more than 50% in comparison with low-dose cyclophosphamide, doxorubicin, and fluorouracil as used in the first study.

[1]  V. Kataja,et al.  Risk for distant recurrence of breast cancer detected by mammography screening or other methods. , 2004, JAMA.

[2]  D. Flum,et al.  Early mortality among Medicare beneficiaries undergoing bariatric surgical procedures. , 2005, JAMA.

[3]  D. Berry,et al.  c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. , 1994, The New England journal of medicine.

[4]  L. Emens,et al.  Trastuzumab in breast cancer. , 2004, Oncology.

[5]  D. Huntsman,et al.  Clinical and molecular predictors of sustained response to trastuzumab in metastatic breast cancer , 2005 .

[6]  B. Gersh,et al.  Interim cardiac safety analysis of NCCTG N9831 Intergroup adjuvant trastuzumab trial , 2005 .

[7]  P. Lønning,et al.  Cognitive ability in childhood and cognitive decline in mid-life: longitudinal birth cohort study , 2003, BMJ : British Medical Journal.

[8]  Richard L Schilsky,et al.  Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Swain,et al.  Ongoing adjuvant trials with trastuzumab in breast cancer. , 2003, Seminars in oncology.

[10]  Jack Cuzick,et al.  Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women , 1988 .

[11]  C. Ko,et al.  Hospitalization before and after gastric bypass surgery. , 2005, JAMA.

[12]  Robin L. Jones,et al.  Efficacy and safety of trastuzumab , 2004, Expert opinion on drug safety.

[13]  D A Berry,et al.  erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. , 1998, Journal of the National Cancer Institute.

[14]  Javier Ballesteros,et al.  Orphan Comparisons and Indirect Meta-analysis: A Case Study on Antidepressant Efficacy in Dysthymia Comparing Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, and Monoamine Oxidase Inhibitors by Using General Linear Models , 2005, Journal of clinical psychopharmacology.

[15]  Giovanni Parmigiani,et al.  Combining Studies with Continuous and Dichotomous Responses: A Latent-Variables Approach , 2000 .

[16]  Barbara L. Smith,et al.  Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Bonetti,et al.  Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. , 2002, Journal of the National Cancer Institute.

[18]  M. Untch,et al.  A monoclonal antibody as an effective therapeutic agent in breast cancer: trastuzumab , 2005, Expert opinion on biological therapy.

[19]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[20]  D. Lauderdale,et al.  Trends in bariatric surgical procedures. , 2005, JAMA.

[21]  E. Perez,et al.  A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer , 2003 .

[22]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[23]  Yu Shen,et al.  Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. , 2005, Journal of the National Cancer Institute.

[24]  S. Assmann,et al.  Subgroup analysis and other (mis)uses of baseline data in clinical trials , 2000, The Lancet.

[25]  Roman Rouzier,et al.  Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Buchanan,et al.  Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  D A Berry,et al.  Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. , 1998, Journal of the National Cancer Institute.

[28]  J. Cuzick,et al.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial , 2002, The Lancet.

[29]  Scott M Berry,et al.  Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysis. , 2003, American heart journal.

[30]  R. Gray,et al.  Annual hazard rates of recurrence for breast cancer after primary therapy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  D. Berry,et al.  Effect of screening and adjuvant therapy on mortality from breast cancer , 2005 .

[32]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[33]  A. Luini,et al.  Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors , 2004, Clinical Cancer Research.